Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Todryk

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Vaccine|April 20, 2011
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccineDavid W Porter, Fiona M Thompson, Tamara K Berthoud, et al.
Plos One|January 31, 2008
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trialFiona M Thompson, David W Porter, Shinji L Okitsu, et al.
Infection and Immunity|April 20, 2006
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite proteinMichael Walther, Fiona M Thompson, Susanna Dunachie, et al.
The Journal of Infectious Diseases|January 26, 2012
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vectorGeraldine A O'Hara, Christopher J A Duncan, Katie J Ewer, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Vaccine|April 20, 2011
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccineDavid W Porter, Fiona M Thompson, Tamara K Berthoud, et al.
Plos One|January 31, 2008
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trialFiona M Thompson, David W Porter, Shinji L Okitsu, et al.
Infection and Immunity|April 20, 2006
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite proteinMichael Walther, Fiona M Thompson, Susanna Dunachie, et al.
The Journal of Infectious Diseases|January 26, 2012
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vectorGeraldine A O'Hara, Christopher J A Duncan, Katie J Ewer, et al.
Pageof 5